De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

De­nali Ther­a­peu­tics had drummed up con­sid­er­able hype for their blood-brain bar­ri­er tech­nol­o­gy since launch­ing over six years ago, hype that’s on­ly in­ten­si­fied in the last 14 months fol­low­ing the pub­li­ca­tions of a pair of pa­pers last spring and proof of con­cept da­ta ear­li­er this year. On Sun­day, the South San Fran­cis­co-based biotech gave the bio­phar­ma world the next look at in-hu­man da­ta for its lead can­di­date in Hunter syn­drome.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER